adct-301
mAbexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2015 (NCT02432235)
Timeline
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Renal Cell · Phase 1
- Colorectal Neoplasms · Phase 1
- Esophageal Neoplasms · Phase 1
- Fallopian Tube Neoplasms · Phase 1
- Hodgkin Disease · Phase 1
- Leukemia, Myeloid, Acute · Phase 2
- Lymphoma, Non-Hodgkin · Phase 1
- Melanoma · Phase 1
- Myelodysplastic Syndromes · Phase 2
- Myeloproliferative Disorders · Phase 2
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Stomach Neoplasms · Phase 1
- Triple Negative Breast Neoplasms · Phase 1
- Urinary Bladder Neoplasms · Phase 1
Mechanism of action
- Peripheral myelin protein 22Immunity, passive
PMP22 immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- adct-301
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04639024 | Phase 2 | Dec 1, 2020 | ADC Therapeutics SARL, Duke University |
| NCT03621982 | Phase 1 | Aug 2, 2018 | ADC Therapeutics SARL |
| NCT02588092 | Phase 1 | Dec 1, 2015 | ADC Therapeutics SARL |
| NCT02432235 | Phase 1 | Jun 1, 2015 | ADC Therapeutics SARL |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ADC Therapeutics SARL | For profit | 4 | 3 | 2 | 2015 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2020 |
2 organizations
Page 1 / 1